The Biggest Risk to Ireland’s Pharma Sector Is No Longer Cost — It’s Confidence

May 18, 2026 - 17:00

EBM Newsdesk Analysis

18 May 2026. Nobody is leaving Ireland yet. MSD, Pfizer, Eli Lilly, Johnson & Johnson — the American pharmaceutical giants that have made Ireland one of the most export-intensive economies on earth are not packing up their plants. But they are pausing. New capital investment decisions are being deferred. Location-of-manufacture decisions for new products are being held. And the industry insiders who know these companies best are being careful about how they phrase what is happening — because the distinction between “not leaving today” and “not investing tomorrow” is the most important economic distinction Ireland faces right now.

Ireland’s pharmaceutical sector is not a minor contributor to the economy. Around 90 companies employ 50,000 people in highly paid roles. Last year, €44 billion in pharmaceutical products were exported directly from Ireland to the United States — roughly half of Ireland’s total global pharma exports. Corporation tax revenues from the sector are a central pillar of Irish public finances. When that sector pauses, the ripple effects move fast and wide.

What Trump Actually Did

The tariff picture is complicated — deliberately so. Trump announced 100% tariffs on branded pharmaceutical imports on the first anniversary of Liberation Day, but the headline rate is misleading. Because Ireland is part of the EU, and the EU has a tariff agreement with the US capping rates at 15%, the practical exposure for most Irish pharma exports is significantly lower than the headline suggests. Generic medicines are currently exempt entirely.

Several of the largest American companies — including Eli Lilly, which has major Irish operations — have already struck private deals with the White House, involving US price commitments and domestic investment pledges in exchange for a reported three-year guarantee of no tariffs. For those companies, the immediate risk is contained.

But for companies that have not done deals, and for the broader investment pipeline, the situation is more precarious. Seventy-five per cent of biopharma businesses in Ireland expect to be directly or indirectly impacted by US tariffs, according to the latest BioPharmaChem Manufacturing Survey. Some companies have already confirmed delayed capital investment. Others are holding location-of-manufacture decisions for new products pending clarity they do not yet have.

The Real Problem Is Uncertainty

The tariff rate itself is almost secondary. What is freezing investment decisions is the unpredictability of how the policy will be applied, enforced, and revised. A 15% tariff is manageable for most pharma companies. A tariff regime that changes month to month, sector by sector, company by company, under opaque criteria that shift based on private White House negotiations — that is genuinely impossible to model.

“The big risk is the somewhat capricious nature of tariff-setting policy in the US,” said one economist. “The 15% rate for the EU could be revisited.” That possibility — not the current rate, but the possibility of an arbitrary change — is what is making CFOs in Dublin and Cork hesitate before signing off on the next major capital commitment. Uncertainty is the enemy of long-term investment. Pharma projects run on ten to fifteen year horizons. You cannot commit to building a new biologics facility in Ringaskiddy if you do not know what the trade environment will look like in 2031.

The Longer-Term Squeeze

The Trump tariff uncertainty is arriving on top of structural pressures that were already building before Liberation Day.

Ireland already pays a premium for energy — EU electricity prices run two to three times higher than in the US and China. Water infrastructure constraints are real and worsening. Housing costs are deterring the talent pipeline the sector needs. And China is not standing still — Chinese-developed molecules now represent nearly a third of the global pharma pipeline, up from just 4% a decade ago. Major pharma companies are licensing Chinese science and accessing Chinese manufacturing at scale. The competitive pressure on Ireland as a manufacturing location is intensifying from multiple directions simultaneously.

The same forces squeezing European industrial competitiveness — high energy costs, regulatory complexity, and competition from heavily subsidised non-European production — are bearing down on Ireland’s flagship sector. The EU’s trade confrontation with China and the disruption caused by US tariff policy are both moving against Ireland’s interests at the same time.

What Needs to Happen

The Irish government’s official position is correct as far as it goes — no immediate cliff edge, ongoing projects continuing, and the EU-US deal providing a partial floor. But the correct official position is not the same as a sufficient strategic response.

What Ireland needs — and does not currently have — is a clear answer to the question that every pharma CFO is asking: why build here rather than in the US? The answer used to be: tax efficiency, skilled workforce, EU market access, regulatory predictability. Tax efficiency is under pressure from global minimum tax reforms. The skilled workforce is expensive and hard to house. EU market access matters less if the US is your primary customer. And regulatory predictability is precisely what Trump has removed.

Ireland holds the EU Council Presidency in late 2026 — an opportunity to shape European competitiveness policy at a moment when the stakes could not be higher. The infrastructure deficits need to be addressed at the pace the sector requires, not the pace Irish planning systems currently permit. And the government needs to be making the argument loudly in Brussels that the EU-US trade framework needs to deliver genuine certainty for pharma — not just a headline rate that Trump can revisit at will.

The companies are not leaving today. The question is whether Ireland gives them a compelling reason to stay tomorrow.

Related Analysis

The post The Biggest Risk to Ireland’s Pharma Sector Is No Longer Cost — It’s Confidence appeared first on European Business Magazine.